Quick Takeaways
- This page summarizes Claire Mazumdar's Form 4 filing for Bicara Therapeutics Inc. (BCAX).
- 9 reported transactions and 3 derivative rows are listed below.
- Filing timestamp: 20 Mar 2026, 17:02.
Claire Mazumdar - 18 Mar 2026 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)
- Signature
- /s/ Lara Meisner, Attorney-in-Fact
- Issuer symbol
- BCAX
- Transactions as of
- 18 Mar 2026
- Net transactions value
- -$282,366
- Form type
- 4
- Filing time
- 20 Mar 2026, 17:02:58 UTC
- Previous filing
- 11 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Claire Mazumdar filed Form 4 for Bicara Therapeutics Inc. (BCAX) on 20 Mar 2026."
What Changed
- Previous filing in this sequence was filed on 11 Mar 2026.
- Current net transaction value: -$282,366.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Mazumdar Claire | Chief Executive Officer, Director | BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON | /s/ Lara Meisner, Attorney-in-Fact | 20 Mar 2026 | 0002034671 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BCAX | Common Stock | Options Exercise | +6,499 | +1.9% | $3.79* | 345,891 | 18 Mar 2026 | Direct | F1 | |
| transaction | BCAX | Common Stock | Sale | $122,415 | -6,499 | -1.9% | $18.84 | 339,392 | 18 Mar 2026 | Direct | F1, F2 |
| transaction | BCAX | Common Stock | Options Exercise | +6,905 | +2% | $3.79* | 346,297 | 19 Mar 2026 | Direct | F1 | |
| transaction | BCAX | Common Stock | Sale | $129,705 | -6,905 | -2% | $18.78 | 339,392 | 19 Mar 2026 | Direct | F1, F3 |
| transaction | BCAX | Common Stock | Options Exercise | +1,596 | +0.47% | $3.79* | 340,988 | 20 Mar 2026 | Direct | F1 | |
| transaction | BCAX | Common Stock | Sale | $30,246 | -1,596 | -0.47% | $18.95 | 339,392 | 20 Mar 2026 | Direct | F1, F4 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BCAX | Stock Option (Right to Buy) | Options Exercise | -6,499 | -3.4% | $0.000000* | 184,608 | 18 Mar 2026 | Common Stock | 6,499 | $3.79 | Direct | F1, F5 | |
| transaction | BCAX | Stock Option (Right to Buy) | Options Exercise | -6,905 | -3.7% | $0.000000* | 177,703 | 19 Mar 2026 | Common Stock | 6,905 | $3.79 | Direct | F1, F5 | |
| transaction | BCAX | Stock Option (Right to Buy) | Options Exercise | -1,596 | -0.9% | $0.000000* | 176,107 | 20 Mar 2026 | Common Stock | 1,596 | $3.79 | Direct | F1, F5 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| F3 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| F4 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| F5 | The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. |